Tvardi Cash Reserves at $30.8M, Sufficient to Fund Operations Through Q4 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Should l Buy TVRD?
Cash, cash equivalents and short-term investments as of December 31, 2025, were $30.8M, as compared to $31.6M as of December 31, 2024. Tvardi anticipates that its current cash runway is sufficient to fund operations, as currently planned, through clinical readouts and into the fourth quarter of 2026. Imran Alibhai, CEO of Tvardi, stated, "We entered 2026 with line-of-site to two significant clinical milestones: 1) healthy volunteer data from our next-generation STAT3 inhibitor, TTI-109, in the second quarter of this year, and 2) topline data from our ongoing Phase 2 trial of TTI-101 in HCC, which we anticipate in the second half."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVRD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVRD
Wall Street analysts forecast TVRD stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 3.390
Low
4.00
Averages
9.00
High
15.00
Current: 3.390
Low
4.00
Averages
9.00
High
15.00
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tvardi Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Improved Financial Performance: Tvardi Therapeutics reported a net loss of $7.3 million for Q4 2025, translating to a diluted loss of $0.78 per share, which is a significant improvement from the $12.7 million loss and $4.94 per share in the same quarter of 2024, indicating progress in cost management and operational efficiency.
- Significant Clinical Progress: The company's STAT3-targeted pipeline, including TTI-109 and TTI-101, is advancing towards multiple key clinical milestones in 2026, with TTI-101 showing clinically meaningful activity in the REVERT LIVER CANCER trial, enhancing investor confidence in its future potential.
- Stable Cash Flow: Tvardi ended 2025 with $30.8 million in cash and short-term investments, expected to fund operations into Q4 2026, ensuring financial stability during the upcoming clinical data readouts.
- Equity Structure Adjustment: The company implemented a 1-for-3 reverse stock split on April 14, 2025, aimed at enhancing stock liquidity and market appeal, although the stock price fell by 0.62% to $3.18 on Tuesday, which may impact investor sentiment.
See More
Tvardi Therapeutics Q4 Earnings Miss Expectations
- Earnings Performance: Tvardi Therapeutics reported a Q4 GAAP EPS of -$0.78, missing expectations by $0.19, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, Tvardi's cash, cash equivalents, and short-term investments totaled $30.8 million, down from $31.6 million in the same period of 2024, reflecting pressure on the company's financial management.
- Funding Strategy: The company anticipates that its current cash runway will be sufficient to fund operations as planned through clinical readouts into Q4 2026, indicating a cautious approach to cash utilization to ensure ongoing operations.
- Future Outlook: Despite financial challenges, Tvardi plans to enhance its market position through advancing clinical trials, which, if successful, could present new growth opportunities for the company.
See More
Tvardi to Present TTI-101 Clinical Data at 44th J.P. Morgan Healthcare Conference
- Clinical Trial Progress: Tvardi Therapeutics will present new Phase 2 REVERT IPF clinical trial data for TTI-101 at the 44th J.P. Morgan Healthcare Conference on January 15, 2026, demonstrating encouraging signals across fibrosis, inflammatory markers, and pulmonary function, further supporting TTI-101's efficacy in inhibiting STAT3.
- Market Demand Alignment: TTI-101, an innovative therapy targeting fibrosis-driven diseases, addresses the urgent need for effective treatment options in the clinical landscape, potentially bolstering the company's market position in the biopharmaceutical sector.
- Investor Engagement: The conference will provide a webcast for investors to access detailed information about TTI-101, likely attracting increased investor interest in Tvardi's clinical advancements and future potential.
- Strategic Positioning: Tvardi's focus on developing small molecule therapies targeting STAT3 highlights its strategic importance in addressing unmet medical needs in fibrosis diseases, which may present long-term growth opportunities for the company.
See More
Tvardi Therapeutics Shares Plunge 80% Following Disappointing Phase 2 Trial Data
- Stock Plunge: Tvardi Therapeutics experienced an over 80% drop in share price on October 13, 2025, following disappointing preliminary data from its Phase 2 REVERT clinical trial, which is likely to severely impact investor confidence and may lead to further legal actions.
- Trial Failure: The trial aimed to assess the safety and efficacy of TTI-101 in patients with idiopathic pulmonary fibrosis, but preliminary results indicated that it did not meet its goals, potentially affecting the company's future R&D direction and funding inflow.
- Investor Losses: Faruqi & Faruqi LLP is investigating potential claims against Tvardi, encouraging investors who suffered significant losses to reach out, highlighting the legal risks that could exacerbate the financial pressures faced by the company.
- Market Reaction: The poor clinical trial results may lead to substantial losses for Tvardi's shareholders, further impacting the company's reputation and market position within the biopharmaceutical industry.
See More
Faruqi & Faruqi Investigates Potential Claims Against Tvardi Therapeutics (NASDAQ:TVRD)
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Tvardi Therapeutics, indicating that the company may face legal risks which could undermine investor confidence.
- Investor Losses Highlighted: The firm encourages investors who suffered significant losses in Tvardi stock or options to contact them directly, demonstrating a commitment to protecting investor rights and potentially leading to increased legal actions from affected investors.
- Industry Impact Assessment: As a leading national securities law firm, Faruqi & Faruqi has recovered hundreds of millions for investors since its founding in 1995, showcasing its influence and expertise in the industry, which may negatively affect Tvardi's market performance.
- Legal Consultation Channels: Investors can reach out via 877-247-4292 or 212-983-9330 for legal advice, providing a clear pathway for affected investors to take action, potentially increasing the number of claims filed against Tvardi.
See More
Tvardi Therapeutics Shares Plunge 80% Following Phase 2 Trial Disappointment
- Stock Plunge: Tvardi Therapeutics, Inc. shares plummeted over 80% on October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial, significantly undermining investor confidence.
- Trial Failure: The study aimed to assess the safety and efficacy of TTI-101 in patients with idiopathic pulmonary fibrosis, but preliminary results indicated that it did not meet its goals, potentially necessitating major adjustments in the company's future R&D direction.
- Patient Characterization Analysis: While baseline characteristics were similar across treatment arms, the lower percent predicted FVC in the placebo group raises concerns about the drug's efficacy, increasing uncertainty for investors regarding future outcomes.
- Legal Investigation Initiated: Faruq & Faruqi LLP has launched an investigation into potential claims against Tvardi, highlighting growing market concerns about the company's future legal risks and financial liabilities.
See More
Tvardi Therapeutics Reports 2025 Financial Results and Pipeline Progress
- Improved Financial Performance: Tvardi Therapeutics reported a net loss of $7.3 million for Q4 2025, translating to a diluted loss of $0.78 per share, which is a significant improvement from the $12.7 million loss and $4.94 per share in the same quarter of 2024, indicating progress in cost management and operational efficiency.
- Significant Clinical Progress: The company's STAT3-targeted pipeline, including TTI-109 and TTI-101, is advancing towards multiple key clinical milestones in 2026, with TTI-101 showing clinically meaningful activity in the REVERT LIVER CANCER trial, enhancing investor confidence in its future potential.
- Stable Cash Flow: Tvardi ended 2025 with $30.8 million in cash and short-term investments, expected to fund operations into Q4 2026, ensuring financial stability during the upcoming clinical data readouts.
- Equity Structure Adjustment: The company implemented a 1-for-3 reverse stock split on April 14, 2025, aimed at enhancing stock liquidity and market appeal, although the stock price fell by 0.62% to $3.18 on Tuesday, which may impact investor sentiment.
See More
Tvardi Therapeutics Q4 Earnings Miss Expectations
- Earnings Performance: Tvardi Therapeutics reported a Q4 GAAP EPS of -$0.78, missing expectations by $0.19, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, Tvardi's cash, cash equivalents, and short-term investments totaled $30.8 million, down from $31.6 million in the same period of 2024, reflecting pressure on the company's financial management.
- Funding Strategy: The company anticipates that its current cash runway will be sufficient to fund operations as planned through clinical readouts into Q4 2026, indicating a cautious approach to cash utilization to ensure ongoing operations.
- Future Outlook: Despite financial challenges, Tvardi plans to enhance its market position through advancing clinical trials, which, if successful, could present new growth opportunities for the company.
See More
Tvardi to Present TTI-101 Clinical Data at 44th J.P. Morgan Healthcare Conference
- Clinical Trial Progress: Tvardi Therapeutics will present new Phase 2 REVERT IPF clinical trial data for TTI-101 at the 44th J.P. Morgan Healthcare Conference on January 15, 2026, demonstrating encouraging signals across fibrosis, inflammatory markers, and pulmonary function, further supporting TTI-101's efficacy in inhibiting STAT3.
- Market Demand Alignment: TTI-101, an innovative therapy targeting fibrosis-driven diseases, addresses the urgent need for effective treatment options in the clinical landscape, potentially bolstering the company's market position in the biopharmaceutical sector.
- Investor Engagement: The conference will provide a webcast for investors to access detailed information about TTI-101, likely attracting increased investor interest in Tvardi's clinical advancements and future potential.
- Strategic Positioning: Tvardi's focus on developing small molecule therapies targeting STAT3 highlights its strategic importance in addressing unmet medical needs in fibrosis diseases, which may present long-term growth opportunities for the company.
See More
Tvardi Therapeutics Shares Plunge 80% Following Disappointing Phase 2 Trial Data
- Stock Plunge: Tvardi Therapeutics experienced an over 80% drop in share price on October 13, 2025, following disappointing preliminary data from its Phase 2 REVERT clinical trial, which is likely to severely impact investor confidence and may lead to further legal actions.
- Trial Failure: The trial aimed to assess the safety and efficacy of TTI-101 in patients with idiopathic pulmonary fibrosis, but preliminary results indicated that it did not meet its goals, potentially affecting the company's future R&D direction and funding inflow.
- Investor Losses: Faruqi & Faruqi LLP is investigating potential claims against Tvardi, encouraging investors who suffered significant losses to reach out, highlighting the legal risks that could exacerbate the financial pressures faced by the company.
- Market Reaction: The poor clinical trial results may lead to substantial losses for Tvardi's shareholders, further impacting the company's reputation and market position within the biopharmaceutical industry.
See More
Faruqi & Faruqi Investigates Potential Claims Against Tvardi Therapeutics (NASDAQ:TVRD)
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Tvardi Therapeutics, indicating that the company may face legal risks which could undermine investor confidence.
- Investor Losses Highlighted: The firm encourages investors who suffered significant losses in Tvardi stock or options to contact them directly, demonstrating a commitment to protecting investor rights and potentially leading to increased legal actions from affected investors.
- Industry Impact Assessment: As a leading national securities law firm, Faruqi & Faruqi has recovered hundreds of millions for investors since its founding in 1995, showcasing its influence and expertise in the industry, which may negatively affect Tvardi's market performance.
- Legal Consultation Channels: Investors can reach out via 877-247-4292 or 212-983-9330 for legal advice, providing a clear pathway for affected investors to take action, potentially increasing the number of claims filed against Tvardi.
See More
Tvardi Therapeutics Shares Plunge 80% Following Phase 2 Trial Disappointment
- Stock Plunge: Tvardi Therapeutics, Inc. shares plummeted over 80% on October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial, significantly undermining investor confidence.
- Trial Failure: The study aimed to assess the safety and efficacy of TTI-101 in patients with idiopathic pulmonary fibrosis, but preliminary results indicated that it did not meet its goals, potentially necessitating major adjustments in the company's future R&D direction.
- Patient Characterization Analysis: While baseline characteristics were similar across treatment arms, the lower percent predicted FVC in the placebo group raises concerns about the drug's efficacy, increasing uncertainty for investors regarding future outcomes.
- Legal Investigation Initiated: Faruq & Faruqi LLP has launched an investigation into potential claims against Tvardi, highlighting growing market concerns about the company's future legal risks and financial liabilities.
See More
